Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8990618 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL2921920 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL384511 | 0.97 | — | — | |
| SCHEMBL45160 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL5135405 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL4092706 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12157423 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL19000749 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12865309 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3359595 | 0.83 | MEN1 (1.00) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5965598-A | PHOTOTHERAPEUTIC AND PHOTODIAGNOSTIC AGENTS AS FREE MOLECULES AND AS CONJUGATES WITH MACROMOLECULAR CARRIER MOLECULES | MOLTENI L. & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A. (IT) | 1999-10-12 | — | — | US | claimed |
| EP-0906758-A1 | Zinc-phthalocyanines and corresponding conjugates, their preparation and use in photodynamic therapy and as diagnostic agents | MOLTENI L. & C. dei Fratelli Alitti Società di Esercizio S.P.A. (IT) | 1999-04-07 | — | — | EP | claimed |
| CN-117794929-A | Selective BCL-XL PROTAC compounds and methods of use | 法国施维雅药厂 | 2024-03-29 | — | — | CN | disclosed |
| CN-107709342-B | Process for preparing acetylgalactosamine acid derivatives | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-113164775-A | Polycyclic compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-108738321-B | GalNAc cluster phosphoramidites | 豪夫迈·罗氏有限公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-108738321-A9 | GalNAc cluster phosphoramidites | 豪夫迈·罗氏有限公司 | 2021-01-29 | — | — | CN | disclosed |
| EP-1719794-B1 | NOVEL POLYMERS AND USES THEREOF | MITSUI CHEMICALS INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| CN-1914253-B | Polymer and use thereof | MITSUI CHEMICALS INC | 2011-08-31 | — | — | CN | disclosed |
| US-7977429-B2 | Polymers and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| CN-101817929-A | Novel polymers and uses thereof | MITSUI CHEMICALS INC | 2010-09-01 | — | — | CN | disclosed |
| US-20070154431-A1 | Novel polymers and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2007-07-05 | — | — | US | disclosed |
| CN-1914253-A | Novel polymers and uses thereof | MITSUI CHEMICALS INC (JP) | 2007-02-14 | — | — | CN | disclosed |
| EP-1719794-A1 | NOVEL POLYMERS AND USES THEREOF | Mitsui Takeda Chemicals, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-5965598-A | PHOTOTHERAPEUTIC AND PHOTODIAGNOSTIC AGENTS AS FREE MOLECULES AND AS CONJUGATES WITH MACROMOLECULAR CARRIER MOLECULES | MOLTENI L. & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A. (IT) | 1999-10-12 | — | — | US | disclosed |
| EP-0906758-A1 | Zinc-phthalocyanines and corresponding conjugates, their preparation and use in photodynamic therapy and as diagnostic agents | MOLTENI L. & C. dei Fratelli Alitti Società di Esercizio S.P.A. (IT) | 1999-04-07 | — | — | EP | disclosed |
| CN-1176644-A | Lewis X derivative and process for producing the same | SUMITOMO PHARMA (JP) | 1998-03-18 | — | — | CN | disclosed |
| EP-0801071-A1 | LEWIS X DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070154431-A1 | Novel polymers and uses thereof | RAD54L, VCL, TYR | MEN1 4310/4885KMT2A 1714/4885TSHR 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.